These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30058029)

  • 1.
    Bensch F; Brouwers AH; Lub-de Hooge MN; de Jong JR; van der Vegt B; Sleijfer S; de Vries EGE; Schröder CP
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2300-2306. PubMed ID: 30058029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
    Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
    Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
    J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
    Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG
    Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of [
    Dehdashti F; Wu N; Bose R; Naughton MJ; Ma CX; Marquez-Nostra BV; Diebolder P; Mpoy C; Rogers BE; Lapi SE; Laforest R; Siegel BA
    Breast Cancer Res Treat; 2018 Jun; 169(3):523-530. PubMed ID: 29442264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    Eisses B; van Geel JJL; Brouwers AH; Bensch F; Elias SG; Kuip EJM; Jager A; van der Vegt B; Lub-de Hooge MN; Emmering J; Arens AIJ; Zwezerijnen GJC; Vugts DJ; Menke-van der Houven van Oordt CW; de Vries EGE; Schröder CP
    J Nucl Med; 2024 Oct; 65(10):1540-1547. PubMed ID: 39237347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
    Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
    J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
    Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
    Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted
    Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS
    Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
    Tamura K; Kurihara H; Yonemori K; Tsuda H; Suzuki J; Kono Y; Honda N; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Hasegawa K; Kanayama Y; Nozaki S; Kinoshita T; Wada Y; Tazawa S; Takahashi K; Watanabe Y; Fujiwara Y
    J Nucl Med; 2013 Nov; 54(11):1869-75. PubMed ID: 24029656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
    J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.